Abstract 181P
Background
Intratumoral tertiary lymphoid structures (TLSs) have been associated with improved outcome in a variety of cancer patient cohorts, reflecting the key role of TLSs in the initiation of tumor-targeting immunity. Although, the clinical and biological relevance of TLSs, B cells, plasma cells and humoral adaptive immunity for patients with EOC have been previously reported, the precise immune contexture of developing TLSs, their impact the phenotypic profile of intratumoral T cells, and their influence on sensitivity to immunotherapy remain to be investigated in detail.
Methods
We harnessed spatial transcriptomics, multiplex immunofluorescence microscopy, and flow cytometry to characterize TLSs in patients with high-grade serous ovarian carcinoma (HGSOC), non-small cell lung carcinoma (NSCLC) and experimental mouse models.
Results
Here, we demonstrate that high-grade serous ovarian carcinoma (HGSOC) contains distinct immune aggregates with varying degrees of organization and maturation. Specifically, mature TLSs (mTLS) as forming only in 16% of HGSOCs with relatively elevated tumor mutational burden (TMB) were associated with an increased intratumoral density of CD8+ effector T (TEFF) cells and TIM3+PD1+, hence poorly immune checkpoint inhibitor (ICI)-sensitive, CD8+ T cells. Converesely, CD8+ T cells from immunologically hot tumors like non-small cell lung carcinoma (NSCLC) were enriched in ICI-responsive TCF1+ PD1+ T cells. Spatial B-cell profiling identified patterns of in situ maturation and differentiation that were associated with mTLSs. Moreover, B-cell depletion promoted signs of a dysfunctional CD8+ T cell compartment among tumor-infiltrating lymphocytes from freshly isolated HGSOC and NSCLC biopsies.
Conclusions
Taken together, our data demonstrate that – at odds with NSCLC – HGSOC is associated with a low density of follicular helper T cells and thus develops a limited number of mTLS that are insufficient to preserve a ICI-sensitive TCF1+PD1+ CD8+ T cell phenotype. These findings point to key quantitative and qualitative differences between mTLSs in ICI-responsive vs ICI-irresponsive neoplasms that may guide the development of alternative immunotherapies for patients with HGSOC.
Legal entity responsible for the study
The authors.
Funding
Sotio Biotech.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
Presenter: Ciro Celsa
Session: Poster Display
112P - Close cardiovascular monitoring during the early stages of treatment for patients receiving immune checkpoint inhibitors
Presenter: Danielle Delombaerde
Session: Poster Display
113P - A multidisciplinary management of immune-checkpoint inhibitor (ICI)-related pneumonitis to improve its clinical management
Presenter: Monica Valente
Session: Poster Display
114P - Real-World Insights on Pan-Cancer Immune Checkpoint Inhibitor Treatment: Initial Findings of a Belgian Multicenter Study
Presenter: Annelies Verbiest
Session: Poster Display
115TiP - MDT-BRIDGE: A phase 2 study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB-IIIB NSCLC
Presenter: Martin Reck
Session: Poster Display
117TiP - BGB-HNSCC-201 (NCT05909904): Phase 2, Open-Label, Multi-Arm, Global Study of Tislelizumab (TIS) + Investigational Agents as First-Line (1L) Treatment in Patients (Pts) With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Presenter: Kevin Harrington
Session: Poster Display
121P - MK-7684A (Vibostolimab [Vibo] Plus Pembrolizumab [Pembro] Coformulation) With/Without Docetaxel in Metastatic NSCLC After Platinum-Chemotherapy (Chemo) and Immunotherapy
Presenter: Nir Peled
Session: Poster Display
123P - A phase II study of nivolumab (N) plus ipilimumab (I) and ASTX727 or N plus I in PD-1/PD-L1 resistant melanoma or NSCLC patients: the run-in phase of the NIBIT Foundation ML1 Study
Presenter: Anna Di Giacomo
Session: Poster Display
124P - Surufatinib plus toripalimab combined with etoposide (E) and cisplatin (P) in patients (pts) with advanced naive small cell lung cancer (SCLC) -Updated results of a phase ?b/? trial
Presenter: Wen Feng Fang
Session: Poster Display